[Results of the clinical study of a new anti-arrhythmia preparation allapinin].
The results of the trial point to a potent and protracted antiarrhythmic effect of allapinin equally pronounced with both intravenous and oral administration to patients with ventricular and supraventricular premature beats. The side effects of the drug in acute tests and during short-term course therapy are not significant.
D000157:Aconitine / Q000031:analogs & derivatives*; D000293:Adolescent; D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D013607:Tablets; D013997:Time Factors
D000889:Anti-Arrhythmia Agents; D013607:Tablets; C051402:allapinin; D000157:Aconitine
Rezul'taty klinicheskogo izucheniia novogo antiaritmicheskogo preparata allapinina.